Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 Jul 21;2(7):100346.
doi: 10.1016/j.xcrm.2021.100346. eCollection 2021 Jul 20.

Spinal muscular atrophy: From approved therapies to future therapeutic targets for personalized medicine

Helena Chaytow  1   2 , Kiterie M E Faller  1   2   3 , Yu-Ting Huang  1   2 , Thomas H Gillingwater  1   2
Affiliations
Review

Spinal muscular atrophy: From approved therapies to future therapeutic targets for personalized medicine

Helena Chaytow et al. Cell Rep Med. .

Abstract

Spinal muscular atrophy (SMA) is a devastating childhood motor neuron disease that, in the most severe cases and when left untreated, leads to death within the first two years of life. Recent therapeutic advances have given hope to families and patients by compensating for the deficiency in survival motor neuron (SMN) protein via gene therapy or other genetic manipulation. However, it is now apparent that none of these therapies will cure SMA alone. In this review, we discuss the three currently licensed therapies for SMA, briefly highlighting their respective advantages and disadvantages, before considering alternative approaches to increasing SMN protein levels. We then explore recent preclinical research that is identifying and targeting dysregulated pathways secondary to, or independent of, SMN deficiency that may provide adjunctive opportunities for SMA. These additional therapies are likely to be key for the development of treatments that are effective across the lifespan of SMA patients.

Keywords: SMN; apoptosis; cytoskeleton; gene therapy; neuromuscular junction; neuroprotection; splicing modulator; ubiquitination.

PubMed Disclaimer

Conflict of interest statement

T.H.G. has served on SMA advisory boards for Roche.

Figures

None
Graphical abstract
Figure 1
Figure 1
Schematic of the main SMN-independent potential therapeutic targets Because of the diverse cellular roles and ubiquitous expression of SMN, SMN deficiency leads to changes in numerous cellular processes and organs, which have been identified as possible therapeutic targets. For clarity, we classified these targets into cellular pathway degradation, neuroprotection, cytoskeleton, muscle, and neuromuscular junction, but some therapies may span over multiple targets.
See this image and copyright information in PMC

References

    1. Verhaart I.E.C., Robertson A., Wilson I.J., Aartsma-Rus A., Cameron S., Jones C.C., Cook S.F., Lochmüller H. Prevalence, incidence and carrier frequency of 5q-linked spinal muscular atrophy - a literature review. Orphanet J. Rare Dis. 2017;12:124. - PMC - PubMed
    1. Lefebvre S., Bürglen L., Reboullet S., Clermont O., Burlet P., Viollet L., Benichou B., Cruaud C., Millasseau P., Zeviani M. Identification and characterization of a spinal muscular atrophy-determining gene. Cell. 1995;80:155–165. - PubMed
    1. Monani U.R., Lorson C.L., Parsons D.W., Prior T.W., Androphy E.J., Burghes A.H.M., McPherson J.D. A single nucleotide difference that alters splicing patterns distinguishes the SMA gene SMN1 from the copy gene SMN2. Hum. Mol. Genet. 1999;8:1177–1183. - PubMed
    1. Lorson C.L., Androphy E.J. An exonic enhancer is required for inclusion of an essential exon in the SMA-determining gene SMN. Hum. Mol. Genet. 2000;9:259–265. - PubMed
    1. Chaytow H., Huang Y.T., Gillingwater T.H., Faller K.M.E. The role of survival motor neuron protein (SMN) in protein homeostasis. Cell. Mol. Life Sci. 2018;75:3877–3894. - PMC - PubMed

Publication types

Substances